Showing 1 - 2 of 2
Tackling dengue threat together
News, Prasert Auewarakul & Vanessa Daniel, Published on 14/06/2025
» In the face of a changing climate, now is the time for Asean member states to develop a cure for dengue.
Unite to solve neglected diseases
Oped, Muhammad Radzi Abu Hassan, Published on 29/04/2025
» The successful collaboration between the health ministries of Malaysia and Thailand, industry partners in Egypt and Malaysia, and the Drugs for Neglected Diseases initiative (DNDi) to bring a new hepatitis C antiviral drug -- ravidasvir -- to market in 2022 was an important milestone. For years, a 12-week course of treatment using sofosbuvir cost between $70,000 (2.34 million baht) and $80,000, putting it out of reach for many in the Global South. But ravidasvir -- a safe and effective alternative when combined with sofosbuvir -- costs far less, averaging less than $500 per course.